Industries de la santé

New citation indicators needed to measure research performance

Imprimer PDF

Écrit par EMBO | 12 Février 2013

HEIDELBERG, 12 February 2013 – How do you compare the impact of a researcher in chemistry or physics with a molecular biologist who may be working on similar projects? In an article published today in EMBO reports two experts support the use of citation indicators that are based on percentiles, a statistical parameter that allows for comparisons with a carefully defined group of reference...

Lire la suite... Ajouter un commentaire

Growing Obese and Geriatric Populations Push up Rate of Diabetes in India

Imprimer PDF

Écrit par GBI Research | 05 Février 2013

India is the second diabetes capital of the world after China, with the treatment market growing at a double-digit year-on-year growth rate, presenting both domestic and Multinational Companies (MNCs) with promising opportunities, states a new report by healthcare experts GBI Research.

Diabetes represents a group of metabolic diseases, characterized by hyperglycemia resulting from...

Lire la suite... Ajouter un commentaire

Geneviève Almouzni to receive the 2013 FEBS | EMBO Women in Science Award

Imprimer PDF

Écrit par EMBO Journal | 05 Février 2013

5 February 2013 – EMBO and the Federation of European Biochemical Societies (FEBS) announce Geneviève Almouzni, deputy director of the Institut Curie in Paris, France, as the winner of the 2013 FEBS | EMBO Women in Science Award.

Professor Almouzni has been recognized for her outstanding contributions to research in the area of histones and chromatin, her engagement in promoting...

Lire la suite... Ajouter un commentaire

Novozymes acquires enzyme business from Canadian Iogen Corporation. The acquisition complements Novozymes’ existing business in the pulp & paper, textile, grain-processing and animal feed industries

Imprimer PDF

Écrit par novozymes | 31 Janvier 2013

Novozymes acquires Iogen Bio-Products, industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million). The deal provides Novozymes with all commercial rights to Iogen Bio-Products’ existing product portfolio, pipeline, facilities and know-how...

Lire la suite... Ajouter un commentaire

FEBS, EMBO and the French Society for Biochemistry and Molecular Biology to hold joint conference in 2014

Imprimer PDF

Écrit par EMBO | 30 Janvier 2013

30 January 2013 – The Federation of European Biochemical Societies (FEBS), EMBO, and the French Society for Biochemistry and Molecular Biology will hold a joint conference for the life sciences in 2014. The FEBS–EMBO 2014 Conference will take place from the 30 August to 4 September at the Palais des Congrès in Paris, France.

The FEBS–EMBO 2014 Conference will be a unique...

Lire la suite... Ajouter un commentaire

The 2013 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the geneticist, Michael Stratton, director of the Wellcome Trust Sanger Institute in Cambridge, and jointly to the German biochemists Peter Hegemann, researcher at the Department of Experimental Bio

Imprimer PDF

Écrit par EMBO | 22 Janvier 2013

The 2013 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the geneticist, Michael Stratton, director of the Wellcome Trust Sanger Institute in Cambridge, and jointly to the German biochemists Peter Hegemann, researcher at the Department of Experimental Biophysics at the Humboldt University, Berlin, and Georg Nagel, researcher at the Institute Julius-von-Sachs at the Biocenter, University...

Lire la suite... Ajouter un commentaire

Novozymes reports EBIT growth of 17%, exceeding outlook

Imprimer PDF

Écrit par Novozymes | 21 Janvier 2013

COPENHAGEN, DENMARK – January 21, 2013 - Novozymes, the world leader in bioinnovation and industrial enzymes, today reported 7% sales growth in 2012 compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook. For 2013, the EBIT margin is expected to remain at its...

Lire la suite... Ajouter un commentaire

New legislation on monitoring medicines’ safety the hot topic at DIA’s EuroMeeting 2013

Imprimer PDF

Écrit par DIA | 15 Janvier 2013

HORSHAM, PA, USA — January 14, 2013 — Amsterdam will play host to more than 3,000 professionals involved in the development of medicines from more than 50 countries at the DIA’s 25th Annual EuroMeeting from March 4-6.

As a neutral global forum EuroMeeting 2013 will feature more than 110 sessions, 200 exhibitors and speakers from the European Medicines Agency, the European Commission...

Lire la suite... Ajouter un commentaire

Scientists discover new diagnostic markers for Kawasaki disease

Imprimer PDF

Écrit par EMBO | 20 Décembre 2012

HEIDELBERG, 20 December 2012 – Researchers have discovered proteins in human urine that offer new opportunities for the diagnosis, study and maybe even the treatment of Kawasaki disease. Mass spectrometry-based proteomic analysis of the human urine proteome, the entire set of proteins found in human urine, uncovered molecular markers that offer significant improvements for the diagnosis of...

Lire la suite... Ajouter un commentaire

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines